155 related articles for article (PubMed ID: 31417682)
1. The Brazilian private pharmaceutical market after the first ten years of the generics law.
Bertoldi AD; Wagner AK; Emmerick ICM; Chaves LA; Stephens P; Ross-Degnan D
J Pharm Policy Pract; 2019; 12():18. PubMed ID: 31417682
[TBL] [Abstract][Full Text] [Related]
2. Brazilian generics market change after Farmácia Popular program.
Bertoldi AD; Chaves LA; Ross-Degnan D; Luiza VL; Emmerick ICM; Silva RMD; Campos MR
Rev Saude Publica; 2019; 53():94. PubMed ID: 31644724
[TBL] [Abstract][Full Text] [Related]
3. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
4. The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysis.
Kaplan WA; Wirtz VJ; Stephens P
PLoS One; 2013; 8(9):e74399. PubMed ID: 24098644
[TBL] [Abstract][Full Text] [Related]
5. Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?
Son KB
Front Public Health; 2023; 11():1120729. PubMed ID: 37601172
[TBL] [Abstract][Full Text] [Related]
6. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of price competition in Italian pharmaceutical off-patent market.
Perna S; Cangini A; Marini R; Guerrizio MA; Da Cas R; Traversa G; Trotta F
Front Med (Lausanne); 2022; 9():1045374. PubMed ID: 36523775
[TBL] [Abstract][Full Text] [Related]
8. The market dynamics of selective serotonin re-uptake inhibitors: a private sector study in South Africa.
Oosthuizen F; Kondiah PJ; Moosa HB; Naroth S; Patel NI; Reddy D; Soobramoney A
Afr Health Sci; 2017 Dec; 17(4):1197-1202. PubMed ID: 29937892
[TBL] [Abstract][Full Text] [Related]
9. Trends in the utilization of medicines sold in the private sector post- registration in South Africa and the implications for similar countries.
Mpanza NM; Godman B; Keele MG; Matlala M
BMC Public Health; 2023 Jan; 23(1):192. PubMed ID: 36709246
[TBL] [Abstract][Full Text] [Related]
10. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India.
Singal GL; Nanda A; Kotwani A
Indian J Pharmacol; 2011 Apr; 43(2):131-6. PubMed ID: 21572645
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of a generic substitution policy implemented in Chile.
Mansilla C; Cárdenas J; Kaplan WA; Wirtz VJ; Kuhn-Barrientos L; Ortíz de Zárate M; Tobar T; Herrera CA
BMJ Glob Health; 2017; 2(Suppl 3):e000922. PubMed ID: 30899555
[TBL] [Abstract][Full Text] [Related]
12. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
13. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
14. Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia.
Kaiser AH; Hehman L; Forsberg BC; Simangolwa WM; Sundewall J
PLoS One; 2019; 14(12):e0226169. PubMed ID: 31834889
[TBL] [Abstract][Full Text] [Related]
15. [What is the real price of SOP and OTC drugs? Pilot study on paracetamol].
Milozzi F; Di Filippo A; Cangini A; Trotta F
Epidemiol Prev; 2023; 47(1-2):57-66. PubMed ID: 36727257
[TBL] [Abstract][Full Text] [Related]
16. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
[TBL] [Abstract][Full Text] [Related]
17. Pseudo-Generics in South Africa: A Price Comparison.
Bangalee V; Suleman F
Value Health Reg Issues; 2019 Sep; 19():87-91. PubMed ID: 31357098
[TBL] [Abstract][Full Text] [Related]
18. The diffusion of generics after patent expiry in Germany.
Fischer KE; Stargardt T
Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
[TBL] [Abstract][Full Text] [Related]
19. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
20. [Price differences between generic and innovator medicines in Brazil].
Vieira FS; Zucchi P
Rev Saude Publica; 2006 Jun; 40(3):444-9. PubMed ID: 16810368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
